Board of Directors

The Board of Directors of Neurosciences Victoria, chaired by Mr Bill Burdett, brings together a balance of scientific, clinical, public policy and commercial expertise.

Mr Bill Burdett AM
BSc (Hons), ASIA
Member, Risk and Audit Committee

Mr Burdett graduated in geology at the University of Western Australia and worked in oil exploration for nine years before moving to Melbourne to start a mining research department for the stockbroking firm of A.C. Goode & Co. He became a partner of the firm and in 1984 was appointed Executive Director in charge of Institutional Sales, Research and Corporate Finance.

Following the sale of A.C. Goode & Co. to the National Australia Bank in 1987, Bill became Founding Chairman and Chief Executive of Burdett, Buckeridge & Young, an institutional stockbroker.

His former appointments include: Director of Investment Technology Group, Inc., Director of IRESS Market Technology Ltd, Director of Nossal Institute Ltd, Council Member of the Nossal Institute for Global Health and Director of the Victorian Neurotrauma Initiative Ltd.
Bill is currently a Director of the Centre for Brain Injury Ltd. and of Australian Friends of Asha Slums.

Mrs Jan West AM
Deputy Chair
Chair, Risk and Audit Committee

Mrs West is a non-executive Director with experience in public sector, community and private organisations.

A Chartered Accountant with 23 years’ experience as a Partner at Deloitte, Jan is a Director of Australian Red Cross, Dairy Australia, Australia Post and Melbourne Forum. She is also an independent member of the Audit and Risk Management Committee of the Victorian Department of Treasury and Finance.

Her experience offers the Board a depth of knowledge and skills in audit, corporate governance, risk and general business acumen. Jan is a past President of The Institute of Chartered Accountants in Australia (ICAA).

She was appointed a Member of the Order of Australia in 2007 and awarded the Governor General’s Centenary Medal in 2001. Jan is a Fellow of Chartered Accountants ANZ and a Graduate Member of the Australian Institute of Company Directors.

Dr Anthony Filippis
BSc (Hons), PhD, MBA
Chief Executive Officer and Managing Director

Dr Filippis obtained his PhD in biochemistry from the University of Melbourne. Following a post-doctoral research fellowship in the USA, Anthony returned to Australia to work in the business and public sector and completed an Masters of Business Administration at La Trobe University, specializing in entrepreneurship and innovation and new venture creation.

Anthony has since held several senior executive roles within ASX-listed, private and start-up companies, including as Executive Director of Senz Oncology Pty Ltd, Chief Executive Officer of Drawbridge Pharmaceuticals Pty Ltd, Head of Corporate Development at Meditech Research Ltd and Vice President of Business Development at Metabolic Pharmaceuticals Ltd.

Anthony has also served as Non-Executive Director for many companies, including neuroscience focused companies, such as Cerebral Therapeutics Pty Ltd and Impel Neuropharma Australia Pty Ltd. Currently, Anthony is a Director of the Centre for Brain Injury Ltd, a member of the Advisory Board of the Melbourne Neuroscience Institute and a member of the Scientific Advisory Council of Biomedical Research Victoria.

Anthony's experience brings a deep understanding and knowledge of the biotechnology, pharmaceutical and investment industries to Neurosciences Victoria.

Ms Debbie Beadle
BSc (Chem) (Hons), FITPA
Member, Risk and Audit Committee

Ms Beadle completed a Bachelor of Science with Honours majoring in chemistry from the University of Melbourne before commencing her training as a patent attorney in 1988. She registered as a patent attorney in 1993 and became a Principal of Griffith Hack in 2003. Debbie has primarily practised as a patent attorney in the fields of chemistry and pharmaceuticals.

From 2009–2011, Debbie held the role of National Practice Group Leader of the Life Sciences and Chemical Group and was elected to the Board of Griffith Hack in November 2011. Debbie is a Fellow of the Institute of Patent and Trade Mark Attorneys of Australia and a member of Ausbiotech, BioMelbourne Network, Royal Australian Chemical Society, Intellectual Property Society of Australia and New Zealand, Asian Patent Attorneys Association, Association Internationale pour la Protection de la Propriété Intellectuelle and the Australian Institute of Company Directors. She is a Director of the Centre for Brain Injury Ltd., a Member of the MS Angels and a Senior Fellow at the Melbourne Law School, University of Melbourne.

Professor Stephen Davis AM
Member, Scientific Council

Professor Davis is the Professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital and the Immediate Past-President of the World Stroke Organization.
He is a Past-President of the Australian and New Zealand Association of Neurologists and the Stroke Society of Australasia.

He received the 2011 William Feinberg Award from the American Stroke Association, the Bethlehem Griffiths Foundation Research Medal in 2011, the 2012 E Graeme Robertson award of the Australian and New Zealand Association of Neurologists, the 2012 Karolinska Award and the 2014 J.J. Wepfer Award. He was elected as a Fellow in the Australian Academy of Health and Medical Sciences in 2015.

He was the 2017 C Miller Fisher Visiting Professor at the Massachusetts General Hospital.

His research is focused on acute therapy for both ischemic stroke and intracerebral hemorrhage, particularly the use of advanced imaging in selection of therapy. He is a consulting editor for Stroke and serves on editorial boards for the International Journal of Stroke, Journal of Clinical Neuroscience and Journal of Neuroimaging. He is the Principal Investigator of an NHMRC stroke program grant. He has co-authored three books, numerous book chapters and around 500 peer-reviewed papers. He was appointed a Member of the Order of Australia in 2013.

Professor Geoffrey Donnan AO
Member, Scientific Council

Professor Donnan is the Director of The Florey Institute of Neuroscience and Mental Health.

He is Professor of Neurology at the University of Melbourne and Head of the Florey Department of Neuroscience and Mental Health, University of Melbourne. His research interest is in clinical stroke management and he was co-founder of the Australasian Stroke Trials Network and Neuroscience Trials Australia.

He is Past President of the Stroke Society of Australasia, the Australian Association of Neurologists and the World Stroke Organization. He has received numerous awards, including the American Stroke Association William Feinberg Award for excellence in clinical stroke research, the World Stroke Organization’s leadership award and the Karolinska Stroke Award for excellence in stroke research.

He was appointed as an Officer within the Order of Australia for his distinguished service to neurology and research contributions and is a Fellow of the Australian Academy of Health and Medical Sciences.

Professor Paul Fitzgerald
Member, Scientific Council

Professor Fitzgerald is Professor of Psychiatry at Epworth Healthcare, Monash University and Deputy Director of Monash Alfred Psychiatry Research Centre. He is a psychiatrist, has a Masters of Psychological Medicine and research PhD.

Paul has been conducting research with transcranial magnetic stimulation (TMS) and other device based treatments for almost 20 years and has run the largest clinical TMS program in Australia for over a decade.

He has conducted over 15 clinical trials in depression, schizophrenia, OCD and other disorders. He has published over 350 journal articles and book chapters and has been cited over 10,000 times. He is also a member of the Scientific Advisory Board of Bionomics Ltd and a founder and board member of TMS.

Professor Graeme Jackson
Chair, Scientific Council

Professor Jackson is Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health. He is a Professorial Fellow of the Florey Department of Neuroscience and Mental Health, University of Melbourne.

His primary research interest is the application of Magnetic Resonance Imaging techniques to the understanding of epilepsy and brain function.

Graeme’s work is recognised for advancing the diagnosis and treatment of patients with epilepsy.

Graeme is a neurologist at the Austin Hospital. He is a recipient of the 2017 American Epilepsy Research Recognition Award for Clinical Science.

Professor Trevor Kilpatrick
Member, Scientific Council

Professor Kilpatrick is a Professor of Neurology and Director of the Melbourne Neuroscience Institute at the University of Melbourne. He is the leader of the Multiple Sclerosis (MS) Division at the Florey Institute of Neuroscience and Mental Health and is a neurologist and Head of the MS Unit at the Royal Melbourne Hospital.

Trevor is a clinician scientist whose basic research focuses on the neurobiology of MS, in particular, glial cell biology and regenerative medicine.

He has initiated a number of productive clinical research projects and established multicentre collaborations to study the genetics and epidemiology of MS and is developing translational platforms for therapeutics that target neurodegenerative diseases.

Mr Howard Ronaldson
BEcon, GradDip Acc&Fin, MBA
Member, Risk and Audit Committee

During 2016 and 2017, Mr Ronaldson served as full-time Chairman of Emergency Services Telecommunications Authority (ESTA), chaired the ESTA Advisory Committee and was a Member of its Finance Committee. Prior to these appointments he served as Administrator at Ambulance Victoria.

Howard has extensive experience at the most senior level of government administration. He was Secretary of the Department of Innovation Industry and Regional Development (DIIRD) from 2008 to 2014. Prior to joining DIIRD, Howard was Secretary of the Department of Infrastructure, a position he held from December 2002.

He has also held senior executive positions in the Department of Premier and Cabinet and as the Director of Gaming, the Director of Crown Lands and the Director of Housing in Victoria. He also worked in Canberra as the Chief Executive and Under Treasurer of the Department of Treasury, Australian Capital Territory.

Professor Christopher Rowe
Member, Scientific Council

Professor Rowe is the Director of Molecular Imaging Research, Department of Molecular Imaging and Therapy, Austin Health and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Melbourne. He has published extensively on SPECT in epilepsy and beta-amyloid imaging in Alzheimer’s disease. He applies state-of-the-art neuroimaging technology to develop and confirm new diagnostic tests and biomarkers. He is a Professorial Fellow, the University of Melbourne and the Florey Institute of Neuroscience and Mental Health.

He is the Neuroimaging Stream Leader of the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) and of the CRC for Mental Health and the former Chair, Neuroimaging Professional Interest Area, US Alzheimer’s Association. In 2011 he received the Kuhl‑Lassen Award, US Society of Nuclear Medicine, for his work in developing a test for the treatment of epilepsy and the diagnosis of Alzheimer’s disease. He is the first Australian researcher to receive a major international award from this Society. In 2015 he received the Christopher Clark Award for Contributions to the Development of Brain Amyloid Imaging at the annual Human Amyloid Imaging Conference, Miami, USA.

Professor Ian Smith
Member, Scientific Council

Professor Smith is Vice-Provost (Research & Research Infrastructure) at Monash University, playing a University-wide leadership role. Previously at Monash University, Ian was a National Health and Medical Research Council-funded Professorial Fellow in the Department of Biochemistry and Molecular Biology, and Deputy Dean (Research) for the Faculty of Medicine, Nursing and Health Sciences.

Ian is an accomplished medical researcher and is recognised as a leader in his field. This research has resulted in over 250 publications and many patents. Ian receives regular invitations to speak at international meetings, many as a plenary speaker. His research has had a direct impact on human health and has led to changes in clinical practice. Ian was a co-founder of a proteomics-based, publicly listed, biotechnology company and he continues to collaborate and consult widely with the pharmaceutical and biotechnology industry. Ian serves on six international editorial boards and over the years he has held office-bearing positions in a number of national and international societies and has had an active involvement in the organisation of numerous national and international scientific meetings. He has held and continues to hold, a variety of national and international senior government and non-government advisory board/committee memberships.